Morton Medvene Kligerman, a distinguished figure in the field of radiology, began his journey in Philadelphia, the city of his birth. Earning his medical degree from Temple University, he briefly imparted his knowledge there before embarking on a significant academic career. In 1950, he was appointed as an assistant professor of radiology at Columbia University, marking the early stages of his impactful contributions to the medical world.
Dr. Kligerman’s career trajectory led him to Yale in 1958, where he assumed the esteemed position of chairman of the department of radiology. He dedicated himself to this role until 1972, after which he embraced a new challenge as the Director of The University of New Mexico Cancer Center. Throughout his career, Dr. Kligerman championed the utilization of radiation and innovative methodologies in cancer treatment, establishing himself as a forward-thinking radiologist.
A notable aspect of his pioneering work was his advocacy for pion therapy. In the 1970s, Dr. Kligerman played a crucial role in overseeing experiments that explored the potential of this approach. Pion therapy involved employing a specialized device to target localized tumors situated in areas challenging to access through conventional surgery or radiation techniques. This method directed a stream of high-energy particles through the body, precisely aimed at the tumor, with the goal of overcoming radiation resistance in specific cancer cells. While initial results of pion therapy were encouraging, further intensive trials did not demonstrate sufficient efficacy to warrant continued pursuit.
Undeterred, Dr. Kligerman’s research interests evolved, leading him to Pennsylvania in the 1980s. There, he delved into the study of WR-2721, a chemical agent designed to mitigate damage to healthy tissues during radiation treatment. He spearheaded successful clinical trials that involved intravenous administration of WR-2721. His extensive lectures on the outcomes of these trials significantly contributed to the understanding and application of this agent, which remains valuable in cancer treatment, particularly for head and neck cancers, as noted by Dr. Hellman.
Dr. Kligerman’s commitment to education was evident in his tenure at The University of New Mexico until 1980. Subsequently, he held professorships at both the University of Pennsylvania and Yale, further solidifying his legacy in oncology and radiology. His life’s work culminated in Philadelphia, where he passed away at the age of 88, leaving behind a remarkable legacy of innovation and dedication to advancing cancer treatment as a pioneering radiologist.
